ACR Appropriateness Criteria® on Metastatic Bone Disease

Catherine C. Roberts, Richard H. Daffner, Barbara N. Weissman, Laura Bancroft, D. Lee Bennett, Judy S. Blebea, Michael A. Bruno, Ian Blair Fries, Isabelle M. Germano, Langston Holly, Jon A. Jacobson, Jonathan S. Luchs, William B. Morrison, Jeffrey J. Olson, William K. Payne, Charles S. Resnik, Mark E. Schweitzer, Leanne L. Seeger, Mihra Taljanovic, James N. WiseStephen T. Lutz

Research output: Contribution to journalReview articlepeer-review

66 Scopus citations


Appropriate imaging modalities for screening, staging, and surveillance of patients with suspected and documented metastatic disease to bone include 99mTc bone scanning, MRI, CT, radiography, and 2-[18F]fluoro-2-deoxyglucose-PET. Clinical scenarios reviewed include asymptomatic stage 1 breast carcinoma, symptomatic stage 2 breast carcinoma, abnormal bone scan results with breast carcinoma, pathologic fracture with known metastatic breast carcinoma, asymptomatic well-differentiated and poorly differentiated prostate carcinoma, vertebral fracture with history of malignancy, non-small-cell lung carcinoma staging, symptomatic multiple myeloma, osteosarcoma staging and surveillance, and suspected bone metastasis in a pregnant patient. No single imaging modality is consistently best for the assessment of metastatic bone disease across all tumor types and clinical situations. In some cases, no imaging is indicated. The recommendations contained herein are the result of evidence-based consensus by the ACR Appropriateness Criteria® Expert Panel on Musculoskeletal Radiology.

Original languageEnglish (US)
Pages (from-to)400-409
Number of pages10
JournalJournal of the American College of Radiology
Issue number6
StatePublished - Jun 2010

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'ACR Appropriateness Criteria® on Metastatic Bone Disease'. Together they form a unique fingerprint.

Cite this